Arthur J. Shannon - Vice President of Investor Relations & Communication Joseph C. Papa - Chairman, Chief Executive Officer and President Judy L. Brown - Chief Financial Officer, Principal Accounting Officer and Executive Vice President

Elliot Wilbur - Needham & Company, LLC, Research Division David Risinger - Morgan Stanley, Research Division Ariel Herman - Goldman Sachs Group Inc., Research Division James B. Dawson - The Buckingham Research Group Incorporated Ami Fadia - UBS Investment Bank, Research Division Joshua Riegelhaupt - Stifel, Nicolaus & Co., Inc., Research Division Gregory B. Gilbert - BofA Merrill Lynch, Research Division David M. Steinberg - Deutsche Bank AG, Research Division Louise Alesandra Chen - Guggenheim Securities, LLC, Research Division Christopher W. Kuehnle - Leerink Swann LLC, Research Division Linda Bolton-Weiser - B. Riley Caris, Research Division

Good morning. My name Melinda, and I will be your conference operator today. At this time, I would like to welcome everyone to the Perrigo Fiscal 2013 Fourth Quarter Earnings Results Conference Call. [Operator Instructions] Thank you. Mr. Art Shannon, you may begin your conference. Arthur J. Shannon: Thank you very much, Melinda. Welcome to Perrigo's Fourth Quarter 2013 Earnings Conference Call. I hope you all had a chance to review our press release, which we issued earlier this morning. A copy of the release is available on our website, and also on our website is a slide presentation for this call. Before we proceed with the call, I'd like to remind everyone that during the process of this call, management will make certain forward-looking statements. Please refer to the important information for investors and shareholders and Safe Harbor language regarding these statements in our press release issued this morning and on Slides 2, 3 and 4 in the accompanying investor presentation. Under Irish Takeover Rules, we are under increased scrutiny between now and the closing, and for those of you accustomed to our regular and open communication disclosure, there will be a change, so please bear with us during this period. Following management's review of the presentation, we will open up the call for questions. I'd like to now turn the call over to the Perrigo's Chairman and CEO, Joe Papa. Joe? Joseph C. Papa: Thank you, Art, and welcome, everyone, to Perrigo's Fourth Quarter Fiscal 2013 Earnings Call. Joining me today is Judy Brown, Perrigo's Executive Vice President and Chief Financial Officer. Today, we're going to spend the majority of our time focused on standalone Perrigo. I will provide a few comments on the quarter, including providing details on our continued sales growth and the strength in store-brand market. Next, Judy will go through the details of the fourth quarter and outline our standalone fiscal 2014 earnings guidance. Then, I will provide an update on each business area, plus an overview of our expectations for the coming fiscal year, and this will be followed by an opportunity for Q&A. However, before I go into Perrigo's fourth quarter, I know many of you have several questions regarding our recently announced definitive agreement to acquire Elan. So let me just spend a few minutes going through some details. Under Irish Takeover Rules, we are limiting in our ability to discuss forward-looking information. Knowing that many of you are seeking a little more detail, this past week, we petitioned the panel to allow us to at least speak to the accretion in the transaction. So assuming the closing to be in the middle of our fiscal 2014, or by the end of the calendar year, in our fiscal 2014, we expect transaction to be at least $0.10 accretive to standalone Perrigo adjusted earnings per share. In our first full year of fiscal 2015, we expect the transaction to be $0.70 to $0.80 accretive to standalone Perrigo adjusted earnings per share. We will be issuing our S-4 in the next few weeks, which will include a pro forma summary which will provide additional details. Since our announcement, we received many questions on why Elan. Turning to Slides 5 and 6, we will explain why. First, we entered into a definitive agreement to acquire Elan to provide us with a platform for growth, both internationally and in the U.S. We would be more competitive to buy assets and pursue other M&A opportunities to further enable future growth. Second, as I just mentioned, it is immediately accretive, with greater than $150 million in merger benefits and synergies. Third, the royalty stream is cash. Cash flow is our core to our business and improves our credit profile. We'll be in an even better position to execute on our strategies for adjacent category and international expansion that we have been laying out for the past 7 years. Adjacent categories will continue to include adult nutrition, diabetes care, pet care, ophthalmics and international growth. This deal does not change our strategy. In fact, it will further enable us to execute on our strategy. Now let's get back to Perrigo's fourth quarter. On Slide 8, you can see that this was, once again, another great quarter for Perrigo, demonstrating the strength of our platform. Our quarterly performance is highlighted by all-time record net sales of $967 million, with a 16% net sales growth, leading to continued record-adjusted profit and more importantly, operating margin expansion. Moving onto Slide 9, it was a historic year for Perrigo, with record top and bottom line results. We recorded a 12% year-over-year improvement in net sales for fiscal 2013 at $3.5 billion, including 6% organic growth despite a delay in several new product launches. The strong sales results correlated with impressive improvements in adjusted gross margin and operating margins, which saw 130 and 110-basis-point improvement, respectively. For the full year, adjusted EPS was $5.61. This performance was driven by great execution, especially within our Rx and Consumer Healthcare business segments. Looking at Slide 10, we continue to generate double-digit sales growth across 3 larger segments, with Consumer Healthcare growing 16% to over $560 million in sales. As you can see on Slide 11, we continue to gain market share and store brands across all categories. Looking at the gastrointestinal market. This category was down 1.4%, and national brands were down 7.3%. But store brand grew 8.5%. Now let's talk about the cough/cold/flu/allergy category. This category has grown 8.2%, and national brands have outgrown store brands. This relatively strong national brand performance in this category is due to certain brands, most notably Mucinex, which is experiencing strong overall results in sales and market share from a combination of core product sales and a number of line extension new products. We are looking forward to our first cough/cold/flu season with our store-brand equivalent to Mucinex 600 milligrams extended release and importantly, the opportunity to launch additional national brand-equivalent cough/cold/flu store-brand products. With that, let me turn the call over to Judy. Judy L. Brown: Thanks, Joe. Good morning, everyone. As you just heard, we wrapped up fiscal 2013 with another record quarter and satisfied the vast majority of the financial metrics we set for ourselves at the beginning of the fiscal year. On a consolidated basis, the team continued its strong performance, delivering record quarterly revenue and adjusted earnings in line with our previously stated guidance for the year. Even without the full year dollar contribution from new product launches we had forecasted at the beginning of fiscal 2013, the team once again demonstrated its ability to execute, highlighted by meeting or exceeding many of the recent guidance ranges provided on our May earnings call. Over the last years, we are also pleased to have successfully delivered on our stated 3-year organic compound annual growth rate goals as well. So as usual, I'll provide a brief overview of the adjusted results for the fiscal fourth quarter by business segment. Then I'll walk you through the consolidated and segment earnings guidance for fiscal 2014 for standalone Perrigo, providing the same level of transparency we do each August on our fiscal year-end calls. So let's begin with the fiscal fourth quarter highlights in the individual business segments, starting on Slide 12 with Consumer Healthcare. The 16% net sales growth was driven by $67 million attributable to the acquisitions of Sergeant's and Velcera; an increase in sales of existing products of $37 million, mainly in contract and smoking cessation categories; and new product sales of approximately $11 million, mainly in the cough/cold and smoking cessation categories. These combined increases were partially offset by a decline of $34 million in sales of existing products in the GI and analgesic categories and $1 million from normal product discontinuations. While we had a late start to the allergy season this calendar year, we saw a strong increase in sales of Loratidine-D, the store-brand version of Claritin-D, due to enhanced consumer awareness on the heels of increased brand advertising and marketing and distribution to certain retailers. The smoking cessation category performed above our expectations, led by the successful launch of the store-brand version of Nicorette Mini Lozenges. Within the GI category, sales of Lansoprazole, the store-brand equivalent to Prevacid, were lower year-over-year as branded marketing and advertising dollars for this product had been more restrained than other competitive proton pump inhibitor products, coupled with the fact that last year's relatively higher sales had the benefit of the retail channel filling and inventory shelf stocking of the Lansoprazole launch. Sales in the analgesics category were somewhat lower due to 3 main reasons. First, a large retailer switched its short-term advertising focus from store brands to national brands; second, a large analgesic manufacturer with a loyal customer base has resumed sales of its product after being absent from the market for a period of time; and third, another large manufacturer that had been absent from the market with numerous products has returned, but with limited availability and SKU volume. Adjusted gross profit grew 31%, while adjusted gross margin increased 410 basis points from the positive contributions of the Sergeant's and Velcera acquisitions, increased manufacturing efficiencies and new product launches. These 3 positive forces were partially offset by lower sales in specific higher-margin products within the categories I just mentioned. The difference between adjusted gross an adjusted operating margin leverage year-over-year was due primarily to the inclusion of operating expenses from Sergeant's and Velcera. Organic or legacy Perrigo distribution, selling, general and administrative expenses were flat on a dollar basis year-over-year. We continued to increase our R&D expenditures though, consistent with our revenue growth, to build our long-term pipeline. On Slide 13, you can see that net sales in the Nutritionals segment grew 11% over last year to $150 million, a new quarterly record. New products contributed approximately half of this dollar growth over last year with more than $2 million of new items brought to shelves in the fiscal fourth quarter. In the U.S., store-brand infant formula's volume share is now 11.6%, with growth of 60 basis points year-over-year and 10 basis points sequentially since fiscal Q3. We continue to gain share despite flat to declining birth rates and continue to receive positive feedback from retailers on our plastic SmarTub containers. We're now shipping approximately 80% of the SKUs of the product to 100% of our U.S. customers. Infant formula sales to China were not in line with our expectations for the quarter, nor were we near our stated goal for the fiscal year as we have continued to work through an extremely dynamic regulatory environment. The team is working very hard though to keep apace of the requirements and maintain product flow. Volumes within the VMS category were strong this quarter as previously announced sales into 2 specific retailers continue to be productive. Adjusted gross margin for the segment decreased 90 basis points year-over-year to 28.9% due to increased cost associated with manufacturing the plastic tub and weaker product mix between our higher-margin infant formula and relatively lower-margin toddler foods and VMS products. I'm pleased to note that steps previously outlined to increase margins have made an impact. The adjusted operating margins increased 150 basis points year-over-year to 16.4%, its highest level since the third quarter of fiscal 2011 and a 570-basis-point increase from last quarter. Again, great job by the Nutritionals team working on margin recovery in the segment. On Slide 14, you can see that our Rx business continues its robust performance as net sales growth was driven by $16 million related to the Rosemont and Fera acquisitions, new product sales of $12 million and strong base business gains of $10 million. Adjusted gross and operating margin expansion continued, increasing 440 and 380 basis points respectively. While the margin contributions from Rosemont and Fera were higher than our Rx-based business, I'm pleased to note that even excluding the impacts from these acquisitions, adjusted gross and operating margins expanded, highlighting continued strength of our existing base business. Now I'd like to focus on the operating results for the API segment and explain the changes you see on Slide 15. We've had a long-standing commercial agreement with a specific customer to supply API for a generic product which was launched in the fourth quarter of our fiscal 2012. As expected, and as a result of the 180-day exclusivity period, adjusted gross and operating profit and margins in the fourth fiscal quarter were negatively impacted year-over-year. However, the team continues its expense management and, of course, we're excited about this Monday's U.S. launch of generic temozolomide, which will be part of the fiscal 2014 guidance I'll walk through in just a moment. The consolidated effective adjusted tax rate for both this quarter and the full year was 28.3%, in line with our expectations. Were you to remove the tax benefits earned in the fiscal first quarter, our fiscal 2013 adjusted tax rate, which is derived primarily from jurisdictional blend of earnings before tax, would have been squarely within our initial guidance range of 29% to 31%. Now I'd like to turn your attention to Slide 16 to discuss fiscal 2014 guidance for the company and by individual segment. While there will be many exciting things to talk about the next weeks and months with respect to our recently announced Elan transaction, I want to focus your attention this morning to our core Perrigo business and our continuing solid growth. So once again, I'll note that these are standalone Perrigo-only numbers without any impact from Elan. So in Consumer Healthcare, we anticipate store brands will continue to be important contributors for growth of our retail customers and, as is our standard practice, our plan includes the assumption that store brand market share will grow approximately 100 basis points over last year. We expect to launch more than 25 new products in CHC, led by the full year contribution of our launched 600-milligram extended release Guaifenesin product, plus the expected launches of the broader family of Mucinex-equivalent products in the back half of the fiscal year. Our guidance also includes the expected launch of store-brand versions of Frontline Top Spot before the next flea and tick season as we are actively selling the store-brand animal health program concept and receiving very positive feedback from our customers. So we expect the animal health category to generate sales of approximately $200 million in fiscal 2014. Balanced against these presumptions, the CHC segment's year-over-year revenue growth range also reflects the impact of the continued return to market of a large, branded analgesics competitor and our assumption that this should continue going forward, in line with the competitor's recent public statements. A reduction in our contract manufacturing business is also built into fiscal 2014 guidance. And as always, I'd like to remind you that our annual planning this year follows the same assumptions we have used in the past with respect to the cough/cold/flu and allergy seasons. In our Nutritionals segment, our revenue guidance includes the assumption that by the end of fiscal 2014, we will grow infant formula store-brand market share and will increase our international presence. This revenue guidance also includes growth greater than 10% in our VMS category, as we continue to expand distribution and launch several new products. For Rx, we anticipate top-line growth driven by new products and recent acquisitions, combined with net price stability in the overall portfolio of existing products. Adjusted margin improvements are expected to be derived from these same factors. Next, API. As we have already noted a few times on this call, on Monday, our partner, Teva, launched the U.S. generic of temozolomide, a brain cancer compound, using our API. This brand today has U.S. sales of approximately $400 million. We anticipate in our fiscal 2014 plan that sales from this product will be recognized starting in our fiscal fourth quarter -- first quarter, that we will have 180-day exclusivity through mid-February, but that we will be competing with an AG in the market on day one. While we're very excited about the launch of this important product, our net sales guidance range also reflects the headwind impact pricing pressure in our existing product portfolio that has affected this segment in the fourth quarter. So this guidance reflects the expectation of only limited new product launches beyond temozolomide and natural competitive dynamics on the rest of our existing product portfolio. Over the longer term, you should expect third-party API revenues to begin to decrease while, at the same time, we will be ramping up intercompany sales to Consumer Healthcare and Rx. Now looking to our consolidated projections on Slide 17. For fiscal 2014, we estimate adjusted diluted earnings per share to be between $6.35 and $6.60, an increase of 13% to 18% compared to fiscal 2013's $5.61. The improvement reflected in the earnings guidance includes an $0.08 benefit of a discrete tax audit resolution in fiscal 2013. Were you to remove these $0.08 of tax benefits earned in fiscal 2013, the 2014 adjusted diluted earnings per share would be projected to increase 15% to 19% year-over-year. Summing everything back up at the standalone consolidated Perrigo P&L, we estimate net sales growth will be between 12% and 16% compared to fiscal 2013 and assume new product sales of greater than $190 million, as well as continued growth in our base business. After you roll up the individual business units, you should also include in your model corporate unallocated expenses of approximately $70 million and interest expense of approximately $85 million. Please note that this interest number reflects the full year impact of our $600 million bond offering from May 2013. Also, please note that we're estimating an adjusted worldwide effective tax rate of approximately 30% to 32% for fiscal 2014, excluding any impacts from the resolution of tax examinations and other statute expirations. This rate takes into consideration the recently announced increase of the Israeli statutory tax rate to 26.5% from 25%, as well as an increase in the rate applicable at so-called privileged enterprise zones from 7% up to 9%. Both of these changes will be effective for the entirety of fiscal 2014. Again, I remind you that this guidance does not take into consideration any tax or interest impacts anticipated by changes in our capital structure following the expected closing of the Elan transaction. As you model the year, please note that our earnings are anticipated to be heavily weighted to the second half of the fiscal year, with many of our new products expected to launch after January. Also, the seasonality in the flea and tick products add to the weight in the fiscal fourth quarter as we plan to launch our broader store-brand offering time for next season. So in summary, we've concluded another record year, which not only saw continued operational excellence progress, but also forward momentum on our stated strategic plans. We made a number of exciting acquisitions in fiscal 2013, launched more than 60 new products, introduced improved SmarTubs in infant formula and broke ground on several important new manufacturing capacity expansion projects. The recently announced planned acquisition of Elan provides us with a great platform to continue growing both domestically, as well as internationally. While we certainly have a very full to-do list at the moment, the buzz of energy in our office is palpable. Very few companies can boast the kind of history as well as future that Perrigo can. With so many avenues of opportunity in front of us, these are certainly exciting times for us all. And let me turn it back to Joe Joseph C. Papa: Thank you, Judy. Now I want to just talk about some of the highlights in our standalone business going forward, beginning with Slide #18. First, let's look at the big picture. We expect the same 3-key growth drivers. Number one, the market continues to shift to store-brand offerings from national brand. Number two, Rx-to-OTC switches are expected to continue, with $10 billion in branded Rx sales likely to switch in the next 5 years, with over $5 billion of that expected in the next 3 years, emphasizing the attractive growth opportunities. We have all seen new categories making the switch, like overactive bladder or the projected-to-switch like nasal inhalers, which recently received a favorable ruling at the FDA advisory meeting. And number three, we expect continued strength in new product launches. The store-brand version of Mucinex launch went very well, and we look forward to the upcoming cough/cold season over the coming months. Additionally, the new product pipeline for fiscal 2014 looks robust. It's highlighted by the expected launches of store-brand versions of children's Delsym, Claritin products, with $135 million in combined branded sales. We anticipate launching over 75 new products across all segments, contributing greater than $190 million in revenue for the coming fiscal year. In our Animal Health business, we are pleased to announce that we have begun shipping our store-brand version of Frontline to a limited number of customers. We expect additional launches in time for the flea and tick season next spring. Turning to Slide #19, you can see that our Nutritionals business has numerous growth drivers in the coming years. A key highlight here is the introduction of the upgraded national brand-style packaging to SmarTub, or the plastic container, which has been very well received by both the retailers and consumers. In fact, the most recent market IRI data demonstrates the impact the new plastic container is having on our U.S. retail business just in the past 12 weeks. Our dollar volume share is up 5.5% versus the fourth quarter last year, and all signs are showing continuing growing momentum as the 4-week data is even stronger. Moving on to our growth opportunities in the Rx segment. On Slide 20, you can see that we continue to be very well positioned. In late July, we launched the generic version of Cutivate, which is approximately $19 million in annual branded sales, and just this week, we received final approval from the FDA for the generic equivalents to Derma-Smoothe Scalp and Derma-Smoothe Body Oil with combined brand sales of $25 million. We expect to begin shipments of both of those products in the next month. We have a robust pipeline of 34 ANDAs pending FDA approval, representing approximately $5 billion in branded sales. This includes 7 confirmed first-to-file ANDAs. Additionally, we have 5 ongoing Paragraph IV challenges. There are more than 8 products that we expect to launch in the coming fiscal year with an anticipated branded sales opportunity of more than $600 million. Additionally, on Slide 21, we have a healthy leadership position across multiple technologies. We have the only FDA-approved generic topical foams, and we will have a full year of contributions from our acquisitions in fiscal year '13, including Rosemont with oral liquid and Fera adding ophthalmic technology to our portfolio. In our API business segment, we are very excited about this week's recent U.S. launch of generic temozolomide, which is a meaningful product to our portfolio with a first-to-file exclusivity. Happily, the launch is going well, and I want to offer my congratulations to the team for bringing this very valuable and essential product to the market. In conclusion, as you can see on Slide #22, Perrigo is poised for continued strong growth. Standalone Perrigo is expected to grow adjusted earnings per share by 13% to 18% this coming year over last year's record performance. The business remains strong, and as we look forward to closing the acquisition of Elan by the end of the calendar year, we will have an even stronger platform for future growth as we continue to execute on our mission of making quality, affordable healthcare, more valuable for consumers and for our customers. Operator, let's now open up the call for questions. Arthur J. Shannon: I'd like to remind everyone too to please try to keep it to one question. Thank you.

[Operator Instructions] Your first question comes from Elliot Wilbur with Needham & Company. Elliot Wilbur - Needham & Company, LLC, Research Division: I know you guys have gone to great lengths to highlight or talk about the organic growth opportunities and potential of the business. But I guess what I'm having a little bit of difficulty with, and I think others as well, is if we think about the string of acquisitions over the past year and just sort of simplistically take what you've talked about in terms of either the fiscal '14 EPS accretion or the first year accretive benefit of these deals and think about products like temozolomide, and add that up and add it to what you reported for fiscal '13, we seem to come up with a lot higher number than even the top end of your current year guidance. So I don't know if that's just an inappropriate exercise to undertake or there's just some things in terms of -- some maybe short-term adjustments in the underlying business such as the return of J&J in the OTC market and stuff that maybe are putting a little bit more short-term pressure on those segments to offset all the acquisition effects and just the underlying organic growth here. So maybe, once again, just kind of hit on what should we be thinking about in terms of core underlying organic growth on -- especially on the operating income line. Joseph C. Papa: Sure. Well, let me start, but I'm going to turn it quickly over to Judy for the commentary on that question. I think first and foremost, you're right. All the same key drivers exist in terms of the movement from national brand to store brand, the Rx-to-OTC and then clearly, new products are all still part of what we think is core to our organic growth driver strategy. So all those components still exists. However, there are some things that we've tried to build into the numbers. And Judy, why don't you kind of go through that in more detail, specific to the other part of Elliot's questions in terms of some of the specifics? Judy L. Brown: Let me -- Elliott, maybe the way to do this is just to break it down very simply in how we think about rolling forward year-over-year. Obviously, we just said we finished up fiscal '13 adjusted EPS of $5.61. This is all on a standalone basis, of course. When you just think about the midpoint of the guidance range that we just provided, you're looking at 16% year-over-year growth. So right off the bat, I talked about the effective tax rate goes up because the Israeli rates went up, there's movement in the jurisdictional rates that we always report on in a heavily U.S. business, and increased interest expense just picking up 11 additional months year-over-year on a $600 million bond. So if you just take those 2 components right off the bat, you got a 7% headwind. So if you think about it, 16% total growth, there's a negative 7% right in there, so you're now looking at 23% year-over-year growth, right? That can be broken down more or less, half-and-half, to think about acquisition contribution bottom line, giving all the numbers that we've already provided at the time of the various announcements over the course of the year last year. So you've got contribution from M&A and you still have -- even after that, you're looking at a number in excess of 10%, 11% of organic growth. So the businesses we have -- we had at the beginning of fiscal '13, still growing around 10% year-over-year. And if you were to break down, on Slide 16 in the materials, and you look at the guidance that we're providing in terms of operating margin expansion business unit by business unit, sales growth business unit by business unit, you know where the M&A happens. And we're still at or beyond the ranges that we've always given in the 3-year compound annual growth. So we feel really good that the guidance reflects the combination of organic growth, the strength of these new products coming through, but still taking in the fact that the reality of interest and tax is weighing against us as we begin the year. And we would be remiss if we didn't include those. So if you put that in your updated model, you may say, "All right. Actually, they're much better in line than I had anticipated." Hope that helps.

Your next question comes from David Risinger with Morgan Stanley. David Risinger - Morgan Stanley, Research Division: I wanted to just ask for a little bit more color, please, on the new product launches that really matter over the next year. So I'm just hoping that you could really discuss 3 areas. First, on Mucinex, I understand that the 600-milligram dose represented about $150 million of a $600-million Mucinex-branded franchise. How much of the other $450 million are you targeting in this fiscal year? I think you had said you're going to be launching more lines within that franchise in the second half. The second part of the question relates to the de-formulations of allergy products. Where do those stand in terms of launches ahead? I know that some had been delayed previously, but which ones should we expect, and when this fiscal year? And then just finally, what are the other big OTC launches we should be thinking about and when in this fiscal year? Joseph C. Papa: Okay. Maybe I'll just move back just a little bit, David, to kind of the starting place. So we expect to launch over 75 new products in our total portfolio for the business, and we specifically expect those products to contribute over $190 million of sales for the total portfolio. So a large number of products clearly are part of our projection for the future. As you get to, though, the specificity that you're asking me -- that you're absolutely on target, the Mucinex 600-milligram extended release, we'll get a full year effect of that. And more importantly, we get the cough/cold/flu season and being in that business during that important part of the season. So that will happen. In addition, we do our planning for additional members of the Mucinex family of products that we expect during the year, but we would caution -- or I caution you that -- Judy was talking about some of those being later in the fiscal year. So we don't have a specific date that we want to put forth at this time, in that, that is a partnered product. But I would be thinking later in the year for that particular product. On the fexo, I think you were -- you asked about the D products, but I believe you meant the fexo D 12-type product. That is a partnered product. And at this time, with our visibility not being complete on that product, I just want to put that product -- it's certainly an important product, but I do not want to put that product -- a specific date on the table for that product at this time. In addition, I think you asked about the other Consumer Healthcare products. There is a host of other products. As Judy mentioned, I think the number, Judy, you mentioned was 30-something, more than 30-something products. Many of them are smaller individual products, to be clear, but they all contribute to our -- putting one more item on the truck as we ship our products to all of our large retailers, and they clearly will continue to add to our operating margin for our business. The final other big product that I wanted to just mention to you in the Consumer Healthcare was the Claritin product that we talked about, a Claritin 24-hour liquigel-type product that we expect to launch. And also, we will launch a store-brand version of the Delsym liquid suspension for pediatrics. So those are the other ones that are probably the ones I could mention at this time. But the other important point is to clearly state that the magnitude of the products are significant numbers of products and will result in that large number of over $190 million of new product sales that we expect in the year.

Your next question comes from Jami Rubin with Goldman Sachs. Ariel Herman - Goldman Sachs Group Inc., Research Division: This Ariel Herman in for Jami. I just wanted to dive a little bit deeper, I guess, into the Consumer Healthcare. If we strip out the animal health sales of Sergeant's and Velcera, we're getting about a 2.5% organic growth rate. So I guess our question is that's a little bit below your mid -- or high-single digit guidance for organic growth rate. So how are you kind of thinking about the organic growth rate? And then just separately, were there any surprises with the pet care business? Judy L. Brown: Maybe I'll take the Consumer Healthcare growth rate. As I look -- obviously, I have more detail than you do in front of me, but if I think about our planning for next year and take out Animal Health, to the comment earlier to Elliott's question, I have the core existing OTC product categories growing squarely in our stated goal of compound annual growth in the 5% to 10% range annually. Obviously, that includes solid base, the normal cycling out, discontinuing of some smaller products, but offset by the reload of the new products that Joe was just talking about. So again, it's going to come down to how much weight you place in your Consumer Healthcare new products contribution, even excluding the Animal Health piece. Joseph C. Papa: And the only thing I would add to the second part of your question on, I think it was specifically, the words were "surprises on pet care," I would say there was no real surprises on pet care. We're delighted with our quarter 4 performance. Was there some delays in -- we did ship our first store-brand flea and tick product. There is more coming. So in that sense, we're delighted with that. Were some of the regulatory hurdles to get the new labeling confirmed there? The answer to that is yes. That is clear. But as we look to the future, we still see some very significant opportunities for our flea and tick products that have come out, both Sergeant's and Velcera acquisitions.

Your next question comes from David Buck with Buckingham Research. James B. Dawson - The Buckingham Research Group Incorporated: It's Jim Dawson for David Buck. In fiscal '13, you talked about some deals you had done, Fera, Velcera, Rosemont, Sergeant's. And you had given an accretion number for fiscal '14, 12 for Fera, 11 for Velcera, 24 for Rosemont and about 20 for Sergeant's. Do those accretion numbers still apply for fiscal '14? Judy L. Brown: Yes. Joseph C. Papa: Yes, the only thing I want to -- yes is the answer. Absolutely correct. Realize that some of those also occurred during the numbers, which we had some Cobrek, Rosemont, Fera sales during the year, so I want to just be careful that it's not -- you got to look at the delta or the difference between years. But Judy's comment is absolutely correct. Judy L. Brown: At the time of each transaction, we tried to give you color on what it was going to contribute to the fiscal year that just ended. And also, in most of those announcements, it was the contribution expected for the first 12 months, i.e., spilling in, in almost every case, spilling into fiscal '14. So those numbers, as stated in those releases with that forward projection, as well as the revenue expectations from those combined activities over the course of those announcements, also applies.

And your next question comes from Ami Fadia with UBS. Ami Fadia - UBS Investment Bank, Research Division: I had 3 quick questions. Firstly, on pet care, I think I heard Judy mention that she's assumed $200 million for fiscal 2014? That seems -- is that correct? Judy L. Brown: That's what we had said at the time of the announcement. Yes. And it just [indiscernible] exactly. Yes. Ami Fadia - UBS Investment Bank, Research Division: Is that what you assumed for the guidance? Because that seems to imply very little growth, considering you're launching a store brand. Joseph C. Papa: Yes. I think -- let me just maybe try to put it in perspective. When we came out with it, we talked about the combination of the Sergeant's and the Velcera as being a $200-million business, which is, I think, exactly what Judy said. Is there an opportunity to grow that business? We said it would be high-single digits prior to the launch of our store brand. But as we launched the total store-brand offerings, it could shift to double digits. And I think that continues to be exactly what we're suggesting. Is there a little bit up and down on that particular one, the answer is yes, but that is -- the ballpark number that we expect is approximately that $200 million level that we talked about. Judy L. Brown: And I made a specific comment, approximately $200 million as a starting point, because we are, as I commented also, rolling out our broader store-brand portfolio launch in that business for the next flea and tick season. While we do anticipate growth, we wanted to be appropriately conservative given that the timing of each of those launches is obviously in a weighted-average basket like we do with any other kind of new product launch. Ami Fadia - UBS Investment Bank, Research Division: Got it. So maybe just the 2 other quick questions. On Nutritionals, could you elaborate a little bit about -- around the growth assumptions in the business that gets you to that 8% to 12%? And then lastly, just if you could split the $190 million of new product launches across the segments? Joseph C. Papa: Okay. I'm going to answer the last one first, but we're not going to break out the more than $190 million by specific segments. We do want to -- because there's no other -- there's no specific one large product that we would point out. It really is looking at the totality of our business. As I said, it's more than $190 million, and it's more than 75 products. But we're not going to -- we don't break it out specifically to segment 1 versus segment 2. On the question of nutrition and the growth factors, I'll just mention quickly that obviously, the important one is the plastic container and the growth from that. But, Judy, why don't you give a little more details on the totality of our Nutritionals? Judy L. Brown: Yes. So Nutritionals as a segment and the guidance on Page 16 in in the slide, is less money than the other 2 big segments because there weren't any acquisitions there in the year. We've got the vitamins and minerals buckets and the infant formula and related products buckets as well. We guided to 8% to 12% top-line growth in total, and suffice it to say that both of those component categories within the segment are expected to grow right now around the midpoint of that range. So it's coming from both categories continuing to grow for the reasons outlined in the earlier comments.

Your next question comes from Annabel Samimy with Stifel. Joshua Riegelhaupt - Stifel, Nicolaus & Co., Inc., Research Division: This is Josh Riegelhaupt in for Annabel. I was hoping you could comment a little bit on your international expansion strategy? Just curious if it's more consumer related, generic related or any other related product segment, and how you kind of plan to drive this with acquisitions as well? Joseph C. Papa: Sure. Well, obviously, the first and foremost comment I would make is that we've got a couple of noteworthy comments. First, number one, is our Elan acquisition we think helps set us up or enable us to even be more effective than our international growth strategy. It also, to be fair, enables us for any M&A opportunity will enable us for. So -- whether it be the adjacent categories or international. But the Elan acquisition probably would be first and form with our commentary in terms of being an enabler for our M&A strategy. As it gets back to the specifics of the international strategy, that becomes very similar to what we've been stating for the past 4, 5 years now. What we simply are seeking to do is take some of the products that we have today, the actual formulation we have today in the United States; bring those product formulations into Europe as an example; get them through the regulatory process, which we've been well underway with that; and then to bring those formulations into -- mostly through partners and other activities that we have to bring those products into Europe. In addition, in the Asia situation, we believe there's a wonderful opportunity for us with our infant formula and our nutritional products in Asia. Clearly, that's where we see the growth in the world's occurring is in Asia in terms of new -- the birthrate in Asia. So we think there's good opportunity in our Nutritionals business in Asia with what we are seeking to do to gain incremental distribution throughout Asia.

Your next question comes from Greg Gilbert with Bank of America Merrill Lynch. Gregory B. Gilbert - BofA Merrill Lynch, Research Division: My question is about the accretion comments you made. And if you can't answer that, I have a backup. So the -- hoping you can offer preliminary amortization, tax rate and operating expense assumptions that are embedded in those comments for '14 and '15? Judy L. Brown: With respect to the transaction? Gregory B. Gilbert - BofA Merrill Lynch, Research Division: Yes. Yes. Specific to the accretion comments that you got approval to make. Judy L. Brown: Oh, Greg. So I'm going to give you the answer, which is at this stage, on this call this morning, I am not, in fact, at liberty to provide that. While I would love to because you can be sure I have a yellow page where I could talk about it, it is -- as part of the process under the Irish Takeover Rules, we won't be able to walk that through. But suffice it to say that the modeling that gives you the components of our expectations as we went through the process will be available to everyone at the same time when the S-4 is published. We expect that to be end of this month, very beginning of September. And then you'll be able to see the analyses that were done in the process of the acquisition by the bank. So that will allow everyone to have that at the same time, and you'll see our presumptions in that process. Gregory B. Gilbert - BofA Merrill Lynch, Research Division: Okay. So my backup question then is can you quantify how much you benefited this past year from the J&J and Novartis disruptions? Because that's -- there was a lot of time spent discussing that in the past. How much did you actually benefit? And then how much did you dial in, in terms of a reversal of that amount for fiscal '14? Joseph C. Papa: Sure. Well, Greg, I don't know if we're going to give you exactly the detail you want, but we'll -- I'll certainly give you my best shot here relative to what it is. And I think as we stated in the past in terms of J&J, it was a $100-million opportunity relative to the store-brand private label opportunity for J&J as a result of their absence from the market. The first year, we did in that $50-million range, so we were somewhat constrained by our ability to make the pediatric liquids. In the second year, we added incremental capacity. However, the season was a very limited. In our third year, we've stated it's in that $50 million to $75 million range in terms of what we were picking up for pediatric analgesic sales, and that was really the primary growth driver for us in the world of what we were trying to do. As we are modeling our fiscal year '14, what we've assumed is that for the commentary of J&J, they would be back in -- they are back in now, and they would be back in with additional products by December of 2013 or are -- the end of calendar year. We have expectations that we will keep approximately 50% of the incremental value that we picked up. The data that we have in terms of talking to consumers to just -- the attitudinal data is a little higher than that, but we felt to be conservative, it would be best to assume that we'd only keep that 50%. As to relate to the second player that has had problems, I think you also asked about Novartis, if I recall the question, you -- they have returned. They started their return in October of 2012, and they certainly have accelerated their return starting in that February, March time frame. They accelerated the return of the Excedrin product. Our expectation is that they will be -- they are back and will be back at their normal levels. So there will be some -- to be candid, that's what we saw in the -- our fourth quarter of fiscal year '13, we saw some return to them, and that's what Judy had mentioned.

Your next question comes from David Steinberg with Deutsche Bank. David M. Steinberg - Deutsche Bank AG, Research Division: Three quick questions. First, on Proair, it seems like a pretty significant opportunity for you with sales over $400 million. Teva just put together its citizens' petition requiring a dose counter. And I was just curious whether you believe your ANDA will also need this dose counter. And if so, how comfortable are you with your current ANDA? Joseph C. Papa: Okay. I'll take that one. Relative to Proair, I absolutely agree with you. We think it's a great opportunity. The product itself, the Albuterol in the metered dose inhaler, has been around for many tens of years. So it's not a raw material or specifically a chemical patent. There is a formulation, some formulation work that they have done. We feel very good, though, that our product that we have put forth to the FDA is an approvable product, and we also like our IP position. I clearly think Teva is a very smart company, and they'll make a lot of decisions along the way. But we like our position relative to both our formulation, as well as our intellectual property position, and that includes all the citizen petitions that they could potentially put forth. We like our position. There always is a question of timing on this issue because any intellectual property and getting through that process takes time, but we like our end position for Proair. David M. Steinberg - Deutsche Bank AG, Research Division: Okay. And then on operating margins. So in the last 4 or 5 years, you've shown significant improvement, well over 100 basis points on average. Just curious whether a reasonable proxy going forward is about 100 bps over the next couple years? Joseph C. Papa: Well, first of all, David, thank you very much for noticing. We do think that's an important contribution that we've been able to do in terms of looking at our success in operating margin. I think -- we've been often asked this question in terms of 100 basis points a year, something like that. Is that a reasonable number? And I guess I go back to the fact that going back, if you look back 6, 7 years ago, the numbers had moved from high-single digits up to the latest number in terms of what we've accomplished being somewhere close to that 23% level. Do I think, though, as we look to the future and as outlined by Judy's guidance, that 100 basis points per year is a reasonable one? Certainly, I would say yes for next year, but I don't want anyone to get too far advanced in terms of driving that number, 100 basis points a year for every year for the next 5 years, because I do think as you get greater numbers, it goes more challenging. So as Judy talked about for next year, that's why we put our range in that 23% to 25% adjusted operating margin. As you go out numerous years, though, I'd be cautious on that until -- it is a very challenging prospect to do that. Judy, you want to make any more comments? Judy L. Brown: David, frankly, with an S-4 coming out in a couple weeks, you'll have the ability to get a little bit of a perspective on how we modeled the next several years on a standalone basis anyway. David M. Steinberg - Deutsche Bank AG, Research Division: Okay. And then one final quick question. So Elan brings you a number of benefits, some of which you can talk about, some you can't, but they also bring you a fiscal year ending December. And just curious whether you could consider changing to a December fiscal year, make it a lot easier for us. And most other companies in the sector of course report in December as well. Joseph C. Papa: I think that's a great question, David. And I think Judy should answer that question because it's one that we've had some numerous discussions on. Judy L. Brown: That's really mean to do to me at the end of this fiscal year when performance review is coming up, David. No, that's a great question because it is also challenging to always be in the fiscal versus the December year end. We are taking it under advisement. There are a lot of activities going on right now. Obviously, with the other required filings, preparing for a transaction close, doing our post -- our integration planning to get ready for day one of being a combined company. So we hear you loud and clear. I know the finance team would really like to have summers free. So with that said, I can't tell you that, that's going to happen in the next 6 months, but it is certainly being taken under advisement for the medium term.

Your next question comes from Louise Chen with Guggenheim. Louise Alesandra Chen - Guggenheim Securities, LLC, Research Division: So I basically was curious. Are you still thinking that mid-teens EPS growth or a range thereof on that factor is something that you're thinking about for the foreseeable future, I guess? Because if I take sort of the midpoint of the range of what you have given for guidance in 2014, and then you assume a mid-teens growth on top of that and then you add on the Elan accretion, obviously, it comes out meaningfully higher than what's in consensus for '15. So just kind of curious, your thinking on that. And then just more on Elan, I don't know if you can answer this but I'll ask anyhow. On the tax rate, I know there are some thoughts that it could go below mid-teens over time. Just curious how low that could go. Is 10% to 20% something that's reasonable -- 10% or so -- 10% to 12% something reasonable over the longer term? Or is that just too low? Joseph C. Papa: Right. You've asked good questions, but very challenging for us to answer at this point in what we say. The only thing I think I could really go back to on the first part of the question, and then, Judy, maybe you could take the tax rate question. What I can go back to on the first part of the question is that what we have stated publicly in terms of our plan is to seek to, over any 3-year period, to grow our business in that 5% to 10% range from an organic point of view. So that -- I think you -- that's really where the basis for your comment came, growing to 5% to 10% on the revenue top line point of view and then seek to double that on the operating income line and on the EPS line, depending obviously on any individual tax changes, of course. But that really is what we've stated. That probably is the best I can do to answer that for future years because I can't obviously make any comments beyond what we're suggesting right now in our 2014 guidance. Judy, the second part of Louise's question was tax. [indiscernible] that? Judy L. Brown: Yes. And just the last color on Joe's comment of that modeling that Joe just said, 5% to 10% top line, 10% to 20% bottom line growth is that compound annual growth that we strive for. We've been layering in acquisitions each year. Now coming to your Elan-specific comment, you did say in your question mid-teens? And I just want to correct that in the announcements related to the acquisition, we said high teens in the first 12 months after acquisition. So just clarifying the point there. And in terms of where the tax rate can go beyond the date of close, I'm really not at liberty to get into forward-looking profit forecast. But just again, going back to the time of the announcement, as with anything related to taxes, jurisdictional mix is always key, and it will be dependent on our ability to continue as a company to grow internationally and take advantage of jurisdictional spread between other countries where the tax rate relatively is low.

And your next question comes from Jason Gerberry with Leerink Swan. Christopher W. Kuehnle - Leerink Swann LLC, Research Division: It's actually Chris Kuehnle in for Jason. Two quick ones. With respect to infant formula, could you maybe provide a little more color on some of the challenges that you're facing in China and when you might envision sales materially increasing beyond I think the previously disclosed figure of tens of millions? And then just a follow-up on the $34-million decline in GI and analgesic, could you give me a sense of the weighting? How much of that is accounted for by the return of a competitor to market maybe versus some of the other factors? Joseph C. Papa: Sure. I'll start with the China question. So first comment on China is there is significant demand for infant formula, product made in the United States or outside of China by the consumers in China. There's been some issues of product that have been made in New Zealand or some active ingredient from New Zealand, other things that have come up. So the demand for our product, which is made in the U.S. of U.S.-sourced raw materials, and specifically the whey protein that we use, is very significant. However, having said that, the regulatory challenges that have been instituted in China also are significant. And I'm very confident that my team will continue to work very hard to work through those regulatory challenges in the China marketplace. So and they deal with labeling questions. They don't deal with the product themselves. Our products are approved in China. It is simply they have amended some labeling claims and labeling information, and the team is working very diligently to get through that. We still think there is a tremendous growth there, to be clear, relative to the demand side, but we are working through the labeling and registration issues that are there. We have worked through the majority of them at this time. However, I can't say that there will not be any incremental labeling questions, and I think those are really specific in what some of the comments that you had. On the second part of your question, on GI, Judy? Judy L. Brown: Yes. Chris, why don't I grab the $34-million question? So earlier, I made that note that, that decline was, again, relative year-over-year, and it's primarily GI and analgesics. On the GI front, it's again a relative year-over-year driver of the Prevacid equivalent product. Remember, launching last time -- this time last year, you got your shelf stocking, your channel fill, et cetera, et cetera. So year-over-year, you see a decline there. On the analgesics side, I made the comment it's 3 pieces. You got one large retailer, switching advertising focus from store to national. You've got a large analgesic manufacturer competitor who had been less active, being now more active relatively year-over-year. And to your point, yet another competitor, more active at this time this year than they were last year. So you've got a couple moving parts there all combining, and that specifically defined GI and analgesics bucket as a decline. Christopher W. Kuehnle - Leerink Swann LLC, Research Division: Great. And would you -- of those factors, would you attribute more to that return of competition or maybe more to the focus on the national brand side? Judy L. Brown: Again, when you've got so many variables, I wouldn't -- if you were trying to simplify, you'd probably weight them evenly. I couldn't say that one is supremely heavier than the other.

And your final question is from Linda Bolton-Weiser with B. Riley. Linda Bolton-Weiser - B. Riley Caris, Research Division: So of the greater than $190 million of new product revenue for FY '14, I'm kind of thinking that the Temodar API is about 1/4 of that. Would that be correct to think about it that way? And are you including that in Rx segment or API segment for the next year? And then secondly, on the over-the-counter business, Prestige Brands, which does branded over-the-counter, they do like PediaCare, they reported in their June quarter that they were already feeling the impact of J&J's return because the retailers are resetting the planogram and the shipments in as J&J gains back shelf space affected them already. So I'm just kind of wondering -- because I thought you said more of the impact would be in the second half of your fiscal year. So I'm just curious, the difference between you and them and that. And then also, I didn't hear you talk about an assumption of normal cough/cold season versus a strong season last year, so I'm assuming you've taken that into guidance, but just wanted to double check on that? Joseph C. Papa: All right. Go ahead, Judy. Why don't you take the... Judy L. Brown: I'm dying to jump in. I'm going to go backwards. Number one, I didn't want to just keep talking and talking and talking on the prepared remarks, but suffice it to say, our planning for this year's cough/cold/flu and allergy season is in fact modeled in our plan precisely the way we've always done it. We take the last 10 years' seasons. We look at the timing and the incidence. We average them, and that's how we build our model. That has not changed, that is still how we go ahead and do our modeling. So that's consistent. Joseph C. Papa: The next one was -- or the first one was about that Temodar, the sales number for that. We don't give out individual numbers, Linda. But to be clear, it is being reported in the API segment. That is the way we report it. I think your number is a little bit high in terms of the percentage, in terms of saying 25%. But I guess it's -- right now, the important comment I'd offer on Temodar that needs to be stated is that we're very excited about the opportunity, to be clear. However, it is -- we have 180-day exclusivity. However, there is an AG in the marketplace, and I think it's very early for us to get too excited about the opportunity for temozolomide. So I think, right now, we're just trying to put it in at a number that is a reasonable number, and then we'll look to see what happens for Temodar going into the future. And then the final part... Judy L. Brown: J&J's return to market. Joseph C. Papa: J&J's return, Judy. Judy L. Brown: The last answer that I just gave to Chris was commenting that in the fiscal fourth quarter relative to the fiscal fourth quarter in the previous fiscal year, part of the dynamic we were seeing in the analgesic category was in fact due to the effect of 2 large branded competitors returning to the marketplace. We are already seeing that, and that was the answer to Q4. We have modeled in our numbers that, that continues and that they continue to return to the market apace of what they have said in their public statements, and that's why my comments earlier were that our model for FY -- fiscal '14 is built on them returning. And then they'll be, in theory, per their statements, "fully back" in the year starting January. So we are seeing that impact already. Joseph C. Papa: Thank you. Let me just close the call. Thank you very much for your interest in Perrigo, and we look forward to providing additional information in November. And thank you for keeping -- and we'll try to keep you updated on our acquisition of Elan. Thank you all for joining us today. Have a great day, everyone.

This does conclude today's conference call. You may now disconnect.